1. Home
  2. SGMO vs MOLN Comparison

SGMO vs MOLN Comparison

Compare SGMO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sangamo Therapeutics Inc.

SGMO

Sangamo Therapeutics Inc.

HOLD

Current Price

$0.50

Market Cap

155.1M

Sector

Health Care

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.57

Market Cap

157.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SGMO
MOLN
Founded
1995
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
155.1M
157.8M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
SGMO
MOLN
Price
$0.50
$4.57
Analyst Decision
Buy
Hold
Analyst Count
7
1
Target Price
$4.71
$4.00
AVG Volume (30 Days)
9.3M
6.0K
Earning Date
11-06-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$32,875,000.00
N/A
Revenue This Year
$1.37
N/A
Revenue Next Year
N/A
$1,000.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.38
$3.36
52 Week High
$2.84
$5.99

Technical Indicators

Market Signals
Indicator
SGMO
MOLN
Relative Strength Index (RSI) 51.55 61.82
Support Level $0.42 $3.99
Resistance Level $0.55 $4.61
Average True Range (ATR) 0.05 0.16
MACD 0.02 0.03
Stochastic Oscillator 67.23 85.71

Price Performance

Historical Comparison
SGMO
MOLN

About SGMO Sangamo Therapeutics Inc.

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: